We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.
- Authors
Lehmann, Sören; Bykov, Vladimir J N; Ali, Dina; Andrén, Ove; Cherif, Honar; Tidefelt, Ulf; Uggla, Bertil; Yachnin, Jeffrey; Juliusson, Gunnar; Moshfegh, Ali; Paul, Christer; Wiman, Klas G; Andersson, Per-Ola
- Abstract
APR-246 (PRIMA-1MET) is a novel drug that restores transcriptional activity of unfolded wild-type or mutant p53. The main aims of this first-in-human trial were to determine maximum-tolerated dose (MTD), safety, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of APR-246.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 29, p3633
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.40.7783